Trial Profile
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Brain metastases; Cognition disorders
- Focus Therapeutic Use
- 20 Feb 2020 Status changed from active, no longer recruiting to completed.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 11 Jan 2019 Planned End Date changed from 1 Sep 2023 to 30 Apr 2023.